Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Non stop selling for 30 minutes now. Wonder why?
This should be huge. Word starting to get around.
NEWS -- Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation
Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that it received FDA orphan drug designation for its ATI-1123 chemotherapy drug product candidate, an albumin-stabilized pegylated liposomal docetaxel, for the treatment of small cell lung cancer.
The FDA’s Orphan Drug Designation Program provides orphan status to drugs, such as ATI-1123, which are intended for the safe and effective treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S. Sponsors of a drug receiving orphan designation qualify for various incentives including tax credits for clinical testing, 7 years of marketing exclusivity following FDA approval, and a waiver of prescription drug user fees.
Small cell lung cancer (SCLC), which accounts for approximately 15% of bronchogenic carcinomas with 33,375 new cases and 23,380 deaths estimated for 2017, has been identified by Cytori as a compelling target for ATI-1123. While SCLC is responsive to chemotherapy and radiation therapy, cure occurs only in ~20% of patients, generally restricted to those with limited stage disease. The remaining 80% of patients, including all patients with extensive disease, relapse within months of completing their initial therapy. Availability of 2nd line therapy options are limited, toxic, and provide little benefit in terms of extending survival. Topotecan is the only FDA-approved agent for 2nd line treatment of SCLC and is associated with an overall response rate of 24%, median response duration or time to progression of 14 weeks, and median overall survival of 25 weeks. Treatment usually involves a consecutive 5 day regimen of either IV or oral administration of drug, both which have black box warnings for severe myelosuppression as their use is associated with substantial morbidity including bone marrow suppression leading to neutropenia, thrombocytopenia and anemia requiring interventions of transfusion and growth factor support.
No major treatment advances for SCLC have occurred over the past 30 years. Hence, there remains a significant unmet need for novel agents with better safety profiles both for patients who cannot tolerate the adverse effects of 1st line chemo-radiotherapy and for relapsed/refractory patients who receive Topotecan. Cytori’s ATI-1123 has been designed to fill this need. ATI-1123’s combination of improved liposome stability, reduced toxicity, and superior delivery are expected to provide a therapeutic for SCLC that offers comparable or better efficacy to currently-available standards while having a less intensive administration routine and improved side effect profile.
Cytori is also exploring the development of ATI-1123 to address the shortcomings of docetaxel, a workhorse chemotherapy drug which generated $2.7B in worldwide sales at its peak. Compared to docetaxel, ATI-1123 may have potential to improve safety by removing the need for unwanted solvents, reduce morbidity by eliminating the requirement for standard pretreatment medications, provide better patient convenience and comfort via less time spent in the treatment center, decrease the cost of therapy, and enhance systemic docetaxel exposure.
A U.S. Phase 1 clinical study of ATI-1123 has been completed and published. Of the 29 patients in the study with cervical, gastric, melanoma, non-small cell lung, ovarian, pancreatic, prostate, thyroid, urachal and uterine cancers, 82% demonstrated a clinical benefit with ATI-1123. ATI-1123 exhibited an improved safety profile versus the Taxotere label with a 31% reduction in neutropenia and anemia. Further, ATI-1123 showed a 20% increase in maximum tolerated dose versus standard docetaxel and signs of efficacy with 1 partial responder.
About Cytori
Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit http://www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, regulatory and reimbursement uncertainties, the challenges inherent in convincing physicians and patients to adopt the new technology, dependence on third party performance, performance and acceptance of our products, and other risks and uncertainties described under the “Risk Factors” in Cytori's Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
mailto://ir@cytori.com
Wonder who or what was behind this pump?
* * $CYTX Video Chart 09-13-18 * *
Link to Video - click here to watch the technical chart video
Receives Orphan Drug Designation
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=649918
CYTX ( D ) Delisted off nasdaq for now. SMH.
Add QTMM first @.04 and after the contract announcement run invest your profits here.
Nice " pop" EOD yesterday. Maybe something is up besides the PPS. I am really torn between just holding my position and adding a lot more here. It is a sink or swim situation.
https://ih.advfn.com/p.php?pid=nmona&article=78176134 rs coming? SMH.
NEWS -- Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
SAN DIEGO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced today that it will present at the 20th Annual Rodman & Renshaw Global Investment Conference at 09:10 AM Eastern Time on Thursday, September 6, 2018. The presentation will take place in the Fontainebleau Foyer room at the St. Regis New York, in New York, NY. Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments. Cytori management will be available for one-on-one meetings at the conference.
About Cytori Therapeutics
Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit http://www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, +1 (858) 458.0900
mailto://ir@cytori.com
I WILL BUY THIS STOCK AT .03 ON THE O T C WHEN I BUY SOME MORE USRM IF THEY ARE STILL IN BUSINESS .....
Congrats! I'm a long long. I appreciate fundamentals but can't argue with anyone taking profits. Thank goodness I have the ability to sit back and watch. Old and comfortable... lol
CYTX
Sold the rest this morning @ .69 Thanks CYTX for over $28K profit..
I don't have much either, there was a lot of accumulation happening this was half an hr before close someone had a hidden bid that show for a few seconds over 200k bid order https://pbs.twimg.com/media/DlOkMfZUYAAqgKc.jpg
We had a great 3 day run refer to the charts. I missed day 1 but the last 2 days have been great. I sold at the close just to be safe but GL.
I have a paltry 3,900 shares. Tempted to jump in deeper but 28 institutional investors have dumped 4.2M shares since 1 Aug. while only 1 has bought in the same time period.
* * $CYTX Video Chart 08-22-18 * *
Link to Video - click here to watch the technical chart video
we could see a reversal base on the daily chart. Could be an epic shorts squeeze on it way with major accumulation
Yep but most biotech / pharma companies have debt. Short interest pushed this thing into the ground. I'd say the bottom is surely in but where it will go from here is anyones guess?
Hi. Do you know why this went down??
New to this one.
This is going to a dollar soon..$CYTX
MOST LIKELY IT WILL BE IN THE .03 AREA BY XMAS AND THEN BANK RUPTCYBY NEXT YEAR !!!!!!!!
* * $CYTX Video Chart 08-21-18 * *
Link to Video - click here to watch the technical chart video
What's up here? CYTX. 52 seeing upside movement
I think the shorts realize it doesn't pay to keep shorting at this level?....the bottom may be in.
So ,whats happen here??!!
Well with the low share structure and funds raised this really should be into the dollars...at least 1 dollar a share and up to say 4-5...doesn't make ANY sense to me! I will hold and add as pps stays low. Strictly a crap shoot in my mind...Bankruptcy or a few bucks a share...I like 50/50 plays.......lol.
Excellent question. Does their patent portfolio and projected milestones warrant this future valuation of price? What's interesting is they've reached the price before their reverse. I'm upside down but continue to hold.
CYTX
How much did they get funds from the last offering?
Ya want to laugh?...read this. Some Analysts have this hitting $14.00 a share!! What century do they think that would happen in?
Analyst Actions: Maxim Group Downgrades Cytori Therapeutics Inc to Hold From Buy
9:36 AM ET, 08/15/2018 - MT Newswires
09:36 AM EDT, 08/15/2018 (MT Newswires) -- Cytori Therapeutics Inc's (CYTX) average rating among analysts is a buy, with an average price target of $14.
Price: 0.38, Change: -0.02, Percent Change: -5.00
YEP, GOOD LITTLE MONEY MAKER .. JUST WAITING FOR IT TO BREAK LOOSE.
These guys go through money like grass through a Goose. Little to show for it from the share price!
YAAAAAAY! ~ NEW 52 WEEK lows! This company is trash.
NEWS -- Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.” This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy™ (ADRCs) in patients with severe voice dysfunction due to scarring of the vocal fold (vocal cords).
The CELLCORDES trial is a fully-enrolled investigator-initiated pilot trial conducted using Cytori Cell Therapy. The trial is being performed by Investigators at the Department of Oto-Rhino-Laryngology and Head and Neck Surgery of Aix-Marseille University and the Cell Therapy Laboratory of La Conception University Hospital, both of Marseille, France. Additional details on the trial may be found at http://clinicaltrials.gov.
The reported index patient had severe vocal dysfunction persisting for four years following traditional surgery to treat chronic vocal fold lesions. Twelve months after single direct administration with 12 million ADRCs, the patient exhibited improvements in Vocal Handicap Index and other qualitative and quantitative measures of voice quality including: Hirano’s GRB scale (measuring vocal hoarseness, roughness, and breathiness), Jitter (a measure of uncontrolled variation in frequency of the voice), and vocal range. The authors noted that while the remaining seven patients treated in the CELLCORDES study have yet to complete 12-months of follow-up, no serious adverse events have been reported in any subject and no subject has reported worsening of vocal function. Furthermore, three are exhibiting “very good results (especially on the VHI)”.
About Cytori
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit http://www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, statements regarding Cytori Cell Therapy’s potential to provide benefits across multiple disease states, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties, which include inherent uncertainties in conduct of clinical studies and trials and the results of such trials (including risks that further studies may not support efficacy or safety of Cytori Cell Therapy), risks associated with clinical use of Cytori Cell Therapy in studies and trials not controlled by Cytori, risks to Cytori’s intellectual property portfolio are described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
CONTACT
CYTORI THERAPEUTICS
Tiago Girao
+1.858.458.0900
mailto://ir@cytori.com
Looks to me like the merciful thing for management to do is sell the company and maybe get some money back to the shareholders. They sure do not seem to know how to get products to market and make money.
* * $CYTX Video Chart 08-03-18 * *
Link to Video - click here to watch the technical chart video
Getting ready to hit the 52 week low. Who's running this company? Bozo?
NEWS -- Cytori to Webcast Second Quarter Financial Results on August 14
Date : 08/02/2018 @ 4:01PM
Source : GlobeNewswire Inc.
Stock : Cytori Therapeutics (MM) (CYTX)
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Tuesday, August 14, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 4075028
Prior to the webcast at approximately 4:30 PM Eastern Time on August 14, Cytori will issue its second quarter earnings release which will review Cytori’s second quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit http://www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
mailto://ir@cytori.com
This company has some great promise. Sadly I feel it is mismanaged and used as a piggy bank by those in charge. The shareholders ( and the medical world ) deserve MUCH better!
what is falling this so much down??
Any hope its going up agane?
NEWS -- Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that its previously announced rights offering (“the Rights Offering”) expired on July 20, 2018 and such rights are no longer exercisable. Cytori accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $6.7 million in gross proceeds. The results of the Rights Offering and Cytori’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Cytori are subject to finalization and verification by Cytori and its subscription agent.
Cytori expects the closing of the Rights Offering will occur on or about July 25, 2018 subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of its Series C Convertible Preferred Stock and warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.
Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series C Convertible Preferred Stock with a stated value of $1,000 (and immediately convertible into common stock at a conversion price of $0.7986 per share, which is equal to 85% of the lowest daily volume weighted average price for Cytori’s common stock, as reported at the close of trading by Nasdaq, during the five trading days prior to the expiration of the Rights Offering (including the expiration date)) and 1,050 warrants. Each warrant entitles the holder to purchase one share of common stock at an exercise price of $0.7986, from the date of issuance through its expiration 30 months from the date of issuance.
Cytori engaged Maxim Group LLC as dealer-manager in the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, or via email at mailto://syndicate@maximgrp.com or telephone at (212) 895-3745.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Cautionary Note Relating to Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements." The words "expects," "believes," "potential," "possibly," "estimates," "may," "could" and "intends," as well as similar expressions, are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that statements which are not strictly historical statements, including, without limitation, statements regarding the completion, timing and size of the Rights Offering, are forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include the ability to satisfy all closing conditions for the Rights Offering, the receipt of the subscription price from investors, our financial condition (including cash runway, our ability to access additional capital to fund our business, and our expectation that we will continue to incur losses at least in the near-term); clinical and regulatory uncertainties (including conduct and results of our clinical trials and investigator-initiated clinical trials using our technology, and challenges in obtaining and maintaining regulatory clearances and approvals for our products); market acceptance of our technologies, including introduction of superior technologies into our anticipated markets; our ability to compete with larger, better financed competitors; dependence on third-party clinical investigators, suppliers and manufacturers; our ability to commercialize and sell products; our compliance with laws, rules and regulations applicable to our business; our ability to attract and retain skilled personnel; our volatile stock price; and our ability to protect and expand our intellectual property rights; and other risks and uncertainties described under the “Risk Factors” in our Securities and Exchange Commission Filings. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any changes in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our registration statement on Form S-1 for the Rights Offering, as well as our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Source: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.
Tiago Girao, 1-858-458-0900
mailto://ir@cytori.com
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2719
|
Created
|
04/07/07
|
Type
|
Free
|
Moderators |
Cytori Therapeutics, Inc. (CYTX)
http://www.cytoritx.com/Home.aspx
Company Information:
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121
Phone: (858) 458-0900
CIK: 0001095981
Cytori Therapeutics, Inc. (NASDAQ: CYTX) represents a unique investment opportunity in both healthcare and regenerative medicine. Broad global access to regenerative medicine has been constrained by a limited availability of stem and regenerative cells. Cytori's team of biologists and engineers have pushed scientific boundaries to overcome the limitation of cell access and allow affordable, real-time access to a patient's own stem and regenerative cells for a potentially unlimited number of medical conditions.
To further this end, we have developed the Celution® System, which takes a patient's own liposuctioned adipose (fat) tissue and separates out the rich concentration of stem and regenerative cells that resides naturally within this tissue. This process is intended to take place primarily at the bedside so that the cells can be re-delivered during the same surgical procedure or preserved for future use.
It is our goal to have a Celution® System in every major hospital and in thousands of specialty medical clinics around the world. Once installed, each device generates recurring revenue from sales of single-use components, a proprietary enzyme solution, and related surgical devices and instrumentation required for each procedure.
Management:
http://www.cytoritx.com/Company/ManagementandCorporateStructure.aspx
Markets & Pipeline:
http://www.cytoritx.com/InvestorRelations/BusinessOverviewCorporateStrategy/MarketsandPipeline.aspx
Press Releases:
http://ir.cytoritx.com/InvestorRelations/releases.cfm
Filings:
Investor Relations:
" />
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |